Drugs / CSR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02930967 | Aug 2016 → Aug 2018 | — | China Meitan General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02930967 ↗ |
| Modality | Cell therapy | “autologous Chimeric Switch Receptor modified T cells (CSR T)” NCT02930967 ↗ |
| Route | Intravenous | “a prescribed dose of CSR T cells will be intravenously infused to patient” NCT02930967 ↗ |